The Latest Breaking News from ISRG

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 2.63% on an annualized basis producing an average annual return of 14.43%. Currently, Intuitive Surgical has a market capitalization of $85.51 billion.

Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ:ISRG) sounded cautious on U.S. capital placements, given rising interest rates and inflationary pressure at hospitals.  "We think this commentary was partly driven by the need to recalibrate Street models for fewer trade-ins as the number of legacy Si systems declines. Overall,…

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns.  On the macro, investor attention seems to be focused less on revenue growth and more…

Within the last quarter, Intuitive Surgical (NASDAQ:ISRG) has observed the following analyst ratings:

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 5.03% on an annualized basis producing an average annual return of 17.59%. Currently, Intuitive Surgical has a market capitalization of $109.71 billion.

Analysts have provided the following ratings for Intuitive Surgical (NASDAQ:ISRG) within the last quarter:

Intuitive Surgical, Inc. (NASDAQ: ISRG) is a global leader in the robotic-assisted surgery market, which is not only large — it is estimated at more than $6 billion — but also the most underpenetrated and fastest-growing among the medical device sub-markets, according to RBC Capital Markets.

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 4.69% on an annualized basis.

Shares of global medical technology pioneer Intuitive Surgical (ISRG) have been foundering of late because investors are concerned about the COVID-19 pandemic’s adverse impact on the company’s procedure volumes. But as the omicron variant threat recedes, will ISRG’s stock be able to regain its forward momentum in the near term?…